Literature DB >> 25071334

Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression.

Ying-Yi Li1, Naofumi Mukaida1.   

Abstract

Pim-3 is a member of the provirus integration site for Moloney murine leukemia virus (Pim) family proteins that exhibit serine/threonine kinase activity. Similar to the other Pim kinases (Pim-1 and Pim-2), Pim-3 is involved in many cellular processes, including cell proliferation, survival, and protein synthesis. Although Pim-3 is expressed in normal vital organs, it is overexpressed particularly in tumor tissues of endoderm-derived organs, including the liver, pancreas, and colon. Silencing of Pim-3 expression can retard in vitro cell proliferation of hepatocellular, pancreatic, and colon carcinoma cell lines by promoting cell apoptosis. Pim-3 lacks the regulatory domains similarly as Pim-1 and Pim-2 lack, and therefore, Pim-3 can exhibit its kinase activity once it is expressed. Pim-3 expression is regulated at transcriptional and post-transcriptional levels by transcription factors (e.g., Ets-1) and post-translational modifiers (e.g., translationally-controlled tumor protein), respectively. Pim-3 could promote growth and angiogenesis of human pancreatic cancer cells in vivo in an orthotopic nude mouse model. Furthermore, a Pim-3 kinase inhibitor inhibited cell proliferation when human pancreatic cancer cells were injected into nude mice, without inducing any major adverse effects. Thus, Pim-3 kinase may serve as a novel molecular target for developing targeting drugs against pancreatic and other types of cancer.

Entities:  

Keywords:  Apoptosis; Cell cycle; Ets-1; Pancreatic cancer; Serine/threonine kinase; Translationally controlled tumor protein; Vascular endothelium growth factor; c-Myc

Mesh:

Substances:

Year:  2014        PMID: 25071334      PMCID: PMC4110571          DOI: 10.3748/wjg.v20.i28.9392

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  108 in total

1.  miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Authors:  Anna M Eiring; Jason G Harb; Paolo Neviani; Christopher Garton; Joshua J Oaks; Riccardo Spizzo; Shujun Liu; Sebastian Schwind; Ramasamy Santhanam; Christopher J Hickey; Heiko Becker; Jason C Chandler; Raul Andino; Jorge Cortes; Peter Hokland; Claudia S Huettner; Ravi Bhatia; Denis C Roy; Stephen A Liebhaber; Michael A Caligiuri; Guido Marcucci; Ramiro Garzon; Carlo M Croce; George A Calin; Danilo Perrotti
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

Review 2.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.

Authors:  Laurent Brault; Christelle Gasser; Franz Bracher; Kilian Huber; Stefan Knapp; Jürg Schwaller
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 4.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update.

Authors:  Craig W Lindsley
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 5.  Heterogeneity of the tumor vasculature.

Authors:  Janice A Nagy; Sung-Hee Chang; Shou-Ching Shih; Ann M Dvorak; Harold F Dvorak
Journal:  Semin Thromb Hemost       Date:  2010-05-20       Impact factor: 4.180

6.  A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Authors:  Ying-Wei Lin; Zanna M Beharry; Elizabeth G Hill; Jin H Song; Wenxue Wang; Zuping Xia; Zhenhua Zhang; Peter D Aplan; Jon C Aster; Charles D Smith; Andrew S Kraft
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

7.  Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.

Authors:  Ying-Yi Li; Ying-Ying Wang; Tsuyoshi Taniguchi; Takahiro Kawakami; Tomohisa Baba; Hiroyuki Ishibashi; Naofumi Mukaida
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

8.  PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications.

Authors:  Min En Nga; Nu Nu Ma Swe; Kang Ting Chen; Liang Shen; Michael B Lilly; Siew Pang Chan; Manuel Salto-Tellez; Kakoli Das
Journal:  Int J Exp Pathol       Date:  2009-10-28       Impact factor: 1.925

9.  Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver.

Authors:  Y Wu; Y Y Wang; Y Nakamoto; Y-Y Li; T Baba; S Kaneko; C Fujii; N Mukaida
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

10.  Pim-3 protects against hepatic failure in D-galactosamine (D-GalN)-sensitized rats.

Authors:  L-M Liu; J-X Zhang; X-P Wang; H-X Guo; H Deng; J Luo
Journal:  Eur J Clin Invest       Date:  2009-12-21       Impact factor: 4.686

View more
  13 in total

1.  Expression of Pim-3 in colorectal cancer and its relationship with prognosis.

Authors:  Zhongguo Zhou; Rongxin Zhang; Ruojing Wang; Yaojun Zhang; Li Xu; Jinbin Chen; Jie Zhang; Zhongxi Huang; Minshan Chen; Zhizhong Pan
Journal:  Tumour Biol       Date:  2016-01-14

2.  Effects of PIM3 in prognosis of colon cancer.

Authors:  Y Zhou; Y N Zhou; S X Liu; J Wang; R Ji; X Yan
Journal:  Clin Transl Oncol       Date:  2021-04-29       Impact factor: 3.405

3.  MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.

Authors:  Chen Liang; Xian-Jun Yu; Xiao-Zhong Guo; Meng-Hong Sun; Zhen Wang; Yao Song; Quan-Xing Ni; Hong-Yu Li; Naofumi Mukaida; Ying-Yi Li
Journal:  Oncotarget       Date:  2015-06-10

4.  Pim-3 Regulates Stemness of Pancreatic Cancer Cells via Activating STAT3 Signaling Pathway.

Authors:  Ting Li; Zhen Wang; Yi-Feng Hou; Ying-Yi Li
Journal:  J Cancer       Date:  2017-06-02       Impact factor: 4.207

5.  MicroRNA-216b-5p Functions as a Tumor-suppressive RNA by Targeting TPT1 in Pancreatic Cancer Cells.

Authors:  Yu You; Jiaxin Tan; Yi Gong; Haisu Dai; Haowei Chen; Xuejun Xu; Aigang Yang; Yujun Zhang; Ping Bie
Journal:  J Cancer       Date:  2017-08-23       Impact factor: 4.207

6.  Ubenimex suppresses Pim-3 kinase expression by targeting CD13 to reverse MDR in HCC cells.

Authors:  Qie Guo; Zhong-Guo Sui; Wen Xu; Xiang-Hua Quan; Jia-Lin Sun; Xiao Li; Hong-Yan Ji; Fan-Bo Jing
Journal:  Oncotarget       Date:  2017-08-10

7.  Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting.

Authors:  Ralf Buettner; Corey Morales; Xiwei Wu; James F Sanchez; Hongzhi Li; Laleh G Melstrom; Steven T Rosen
Journal:  Mol Ther Oncolytics       Date:  2019-05-17       Impact factor: 7.200

8.  Pim-3 alleviates lipopolysaccharide-stimulated AR42J pancreatic acinar cell injury via improving the inflammatory microenvironment.

Authors:  Jie Jian; Shuang Li; Nian Fang; You-Zhao Cao; Li Zhen; Jian-Bin Qin; Bin Li
Journal:  Exp Ther Med       Date:  2019-10-10       Impact factor: 2.447

9.  Pim-3 is a Critical Risk Factor in Development and Prognosis of Prostate Cancer.

Authors:  Yanchun Qu; Changwen Zhang; E Du; Andi Wang; Yuming Yang; Jianing Guo; Aixiang Wang; Zhihong Zhang; Yong Xu
Journal:  Med Sci Monit       Date:  2016-11-09

10.  Pim-3 as a potential predictor of chemoradiotherapy resistance in locally advanced rectal cancer patients.

Authors:  Rong-Xin Zhang; Zhong-Guo Zhou; Shi-Xun Lu; Zhen-Hai Lu; De-Sen Wan; Zhi-Zhong Pan; Xiao-Jun Wu; Gong Chen
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.